INTRODUCTION
Bacterial conjunctivitis is an inflammation of the conjunctiva, characterised by persistent mucopurlent discharge and redness of the eye 1 . It is generally a selflimiting disease and usually does not cause permanent loss of vision or structural damage to eye. Topical antibacterial is used to overcome this disease 2, 3 .Bacterial conjunctivitis caused by those bacteria which infect the eye through various sources of contamination. Besifloxacin ophthalmic suspension 0.6%w/v was approved by US-FDA in 2009. The formulation uses Duracite ® technology to increase the residence time of drug on theocular 7, 8 .Besifloxacin is a novel fluoroquinolone antibiotic for ocular pathogens that are currently resistant to present fluoroquinolone antibiotics 9 .
Besifloxacin (7-[(3R)-3-aminohexahydro -1H-azepin -1-y1] -8 -choloro -1-cyclopropyl -6-fluoro -1,4-dihydro -4-oxo-3-quinolinecarboxylic acid )-(figure 1)is a novel, chiral synthetic fluoroquinolone being developed by Bausch & Lomb for the topical treatment of ophthalmic infections. Structurally, besifloxacin has an N-1 cyclopropyl group, which provides broad-spectrum activity against aerobic bacteria 10 . The main mechanism of action of besifloxacin is the inhibition of DNA gyrase and topoisomerase-IV enzyme that are involved in bacterial transcription replication and separation of chromosomal DNA during cell division 10 . This activity is enhanced by a C-8 chloride substituent in besifloxacin, which also exhibits improved activity against grampositive bacteria relative to older fluoroquinolone while still remaining potent efficacy against anaerobic bacteria 11 . 12 investigated mechanism of action of BSF in Streptococcus pneumoniae and Staphylococcus aureus and found that BSF inhibit both enzyme DNAgyrase and topoisomerase-IV. Microbial data reports that besifloxacin have a relatively high potency and rapid bactericidal activity against conjunctivitis causing agents or bacteria 13 . However, this review article provides an overview of the pharmacologic and pharmacokinetic properties, clinical efficacy, and tolerability of besifloxacin 0.6% ophthalmic suspension along with HPLC and microbiological validation of besifloxacin bioassay. 
METHODS OF CITATION
The reports related to pharmacology, efficacy, tolerability and validating methods like HPLC and by Bioassay.
Microbiological assay of besifloxacin obtained through a search of PubMed, Medline, International Pharmaceutical Abstracts , Willey Library Online, Science Direct , Drug Review of R & D of besifloxacin and searching FDA website using the term besifloxacin, besivance, besix, bacterial conjunctivitis, HPLC methods of besifloxacin, microbiological assay of besifloxacin , mechanism action of besifloxacin, SAR of besifloxacin, safety and tolerability of ophthalmic suspension of besifloxacin, spectrum of besifloxacin, causative agents of bacterial conjunctivitis, ADR of besifloxacin, marketed products of besifloxacin HCL and dose administration of ophthalmic suspension of besifloxacin.
PHARMACOKINETIC PARAMETERS
Ward et al. 11 reported after instillation of a single dose of 0.6% ophthalmic suspension of besifloxacin in rabbit's eye and determined the ocular pharmacokinetic parameter of besifloxacin. These ocular pharmacokinetic parameter like C max, AUC, Mean residence time (MRT) of drug were studied in aqueous humours, tears and in plasma ( Table 1) . 
NA = Not available
Among the plasma, aqueous humours, conjunctiva and tears, very low concentration of besifloxacin (<10 µg/ml) was found in plasma after single dose, so it confirming minimal systemic exposure after ocular administration. The drug concentration in conjunctiva was more than plasma and aqueous humour and less than the concentration obtained in tears. The result of these simulation indicated that a thrice daily dosing regimen was sufficient to achieve conjunctival besifloxacin concentration of 2µg/g that were consistently above the MIC 90 for most ophthalmologic.
Prokesh et al. 14 evaluated by administrating one drop of besifloxacin ophthalmic suspension 0.6% in each eye 3-times daily for 5-days with a final dosing on 6 th day in a subject with bacterial conjunctivitis. In another study a single topical ocular administration was given and found that the besifloxacin was rapidly absorbed (T max =0.5 hour) and sustained concentration in tears of besifloxacin was found to be of <0.05 µg/ml that were maintained through 24 hours. The mean plasma concentration was 12-15 folds lower in human than in the experiment in rabbits and monkey. The in-vitro protein binding of besifloxacin in human plasma ranges from 38.5% -44.0% (Table 2 ). 
CLINICAL SAFETY AND EFFICACY
The clinical safety and efficacy of 0.6% ophthalmic suspension of besifloxacin in the treatment of bacterial conjunctivitis was studied and reported by Tepedino et al. 8 , Karpeci et al. 15 , McDonald MB et al. 16 15 and McDonald MB et al. 16 conducted a prospective, randomised, double masked, vehicle-controlled parallel group trial for a 5 days for evaluating the clinical safety, efficacy and microbiological inhibitory action of 0.6% ophthalmic suspension of besifloxacin in the treatment of bacterial conjunctivitis.
In their trial study 269 patients were selected for treatment (137-Besifloxacin, 132-Vehicle), however among them only 256 subjects completed the trial (134-Besifloxacin, 122-Vehicle) respectively. Where in the culture-confirmed study intent to treat population consisted of 118 patients (60-Besifloxacin 0.6% ophthalmic suspension and 58-Vehicle controlled) respectively. In this study the female subjects were (60.2%) in which white were 82.5%, with mean age 34.2 years 8, 15 . During this trial more patients were received 0.6% ophthalmic suspension of besifloxacin, as compared to vehicle. The clinical resolution of the baseline infection at visit -3 was found to be 15 studied and reported that 0.6% ophthalmic suspension of besifloxacin, administered 3 times daily for 5 days was both efficacious and well tolerated as compared with vehicle in the treatment of patients with bacterial conjunctivitis. However, treatment with besifloxacin that was reported by Karpeci et al. were to be well tolerated, with no apparent differences compared with vehicle in terms of clinically significant changes in visual acuity or treatment-emergent events on bio microscopy or direct ophthalmoscopy. In addition, besifloxacin ophthalmic suspension 0.6% administered two-times daily for 3-days was clinically more effective than the vehicle alone for bacterial conjunctivitis. However, Tepedino et al. found 0.6% ophthalmic suspension of besifloxacin to be well tolerated in patients with bacterial conjunctivitis. Rate of absence of ocular discharge and eradication of the baseline infection were higher with 0.6% ophthalmic suspension of besifloxacin as compared to the vehicle. On the basis of earlier reporting Khimdas et al. 17 concluded that the besifloxacin is safe and efficacious for the treatment of bacterial conjunctivitis in patients without any bacterial resistance.
Malohotra et al. 18 also conducted randomized, multicentre, double masked, vehicle controlled, parallel group study on 518 selected subjects with mean age of ≥ 1 years. In trial study, patients were randomized into 2:1 to treatment with besifloxacin 0.6% ophthalmic suspension and vehicle for 7 days, through instilled one drop to infected eyes. They reported that besifloxacin 0.6% ophthalmic suspension is safe in patient to treat bacterial conjunctivitis infected eyes, when used three times daily for seven days.
COMPARISION WITHDIFFERENT FLUOUROQUINOLONEAND VEHICLE
McDonald MB et al. 16 conducted a prospective, randomized, double-masked, active-controlled, parallelgroup, non-inferiority trial to compared the clinical and antimicrobial efficacy of 0.6% ophthalmic suspension of besifloxacin and 0.5% ophthalmic suspension of moxifloxacin, by administered both 3 times daily for 5 days, in the treatment of bacterial conjunctivitis. However, McDonald MB et al. found that 0.6% ophthalmic suspension of besifloxacin to be noninferior in tolerability and efficacy to 0.5% ophthalmic solution of moxifloxacin in the treatment of bacterial conjunctivitis. There were no significant differences found in rates of absence of ocular discharge and eradication of the baseline microbial infection between the two treatment groups. ISSN: 2250-1177 CODEN (USA): JDDTAO Torkildsen G et al 19 conducted a trial to compared the pharmacokinetic parameter of besifloxacin, gatifloxacin and moxifloxacin and found that these fluoroquinolone were well tolerated in patients.
Silverstein et al. 20 reported that besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days leads significantly higher rates of clinical resolution and bacterial eradication as compared with vehicle and also was well tolerated, Besivance® and Besix® two different marketed brands was formulated by 'Duracite' technology containing 0.6% sterile ophthalmic suspension of besifloxacin which are available in 5 ml of sterile packing. Each ml of 0.6% suspension contains 6.63 mg of besifloxacin hydrochloride equivalent to 6 mg of the drug. The suggested dose is one drop to the bacterial infected eye, 3 times daily for 7 days 25 . Besifloxacin is only recommended for topical ophthalmic use and should not be injected sub conjunctively, nor should it be introduced directly into the anterior chamber of the eye. Patients who have signs and symptoms of bacterial conjunctivitis should not wear contact lenses. During the time of administration invert the close bottle, as well as suspension bottle must be shake once before use.
ANALYSIS OF BESIFLOXACIN
Arnold et al. 26 quantitatively determined besifloxacin in human tear by liquid chromatography by using sparfloxacin as the internal standard. Calibration standard were prepared by spiking schirmer strips containing the artificial tear solution with known concentration of besifloxacin. In this study tear sample was collected from 64 healthy subject following topical ocular administration of 0.6% besifloxacin hydrochloride in both eyes with the aid of spiking schirmer strips and then analyzed by LC/MS/MS. This artificial tear strip was weighed before and after tear collection and the test strip were store at −20 0 C until the sample were analyzed. However, the reported quantitative analysis of besifloxacin in human tear sample was found to maximum level was 610±540 µg/g after topical administration of 0.6% ophthalmic suspension and tear sample were collected and analyzed 24 hours after dosing, the method was précised and economical with short run time 4 minutes and applied for topical ocular pharmacokinetic of besifloxacin. Costa C. N. et al. 27 reported the development and validation of microbiological assay method that was compared with high performance liquid chromatography (HPLC) method. The study was based on the inhibitory effects of besifloxacin on the strain of Staphylococcus epidermidis (ATCC1228). The standardization procedure was based on the protocol of Brazilian Pharmacopoeia2010and USP-2009 ( 
CONCLUSION
Besifloxacin is a new broad-spectrum, bactericidal, topical ophthalmic fluoroquinolone approved for the treatment of bacterial conjunctivitis. Besifloxacin ophthalmic suspension was well tolerated in patients with a minimal ocular adverse effect. In addition to its broad spectrum of activity, clinical safety, efficacy and good tolerability of besifloxacin having also antiinflammatory activity through inhibition of proinflammatory cytokines 30 and also through inhibition of the nuclear factor KB and mitogen activated protein kinase pathway. The low minimum inhibitory concentration and high attainment of pharmacodynamics target with besifloxacin may contribute to a lower risk for the emergence for the bacterial resistance, although further studies are required. Fluoroquinolone, particularly besifloxacin, gatifloxacin and moxifloxacin have become important treatment option for common
